RAAS in diabetic retinopathy: mechanisms and therapies
Arch. endocrinol. metab. (Online)
; 68: e230292, 2024. graf
Article
in En
|
LILACS-Express
| LILACS
| ID: biblio-1556932
Responsible library:
BR1.1
ABSTRACT
ABSTRACT Diabetic retinopathy (DR) is a complication of diabetes with a complex pathophysiology and multiple factors involved. Recently, it has been found that the upregulation of the renin-angiotensin-aldosterone system (RAAS) leads to overexpression of angiotensin II (Ang II), which induces oxidative stress, inflammation, and angiogenesis in the retina. Therefore, RAAS may be a promising therapeutic target in DR. Notably, RAAS inhibitors are often used in the treatment of hypertension. Still, the potential role and mechanism of DR must be further studied. In this review, we discuss and summarize the pathology and potential therapeutic goals of RAAS in DR.
Full text:
1
Collection:
01-internacional
Database:
LILACS
Language:
En
Journal:
Arch. endocrinol. metab. (Online)
Year:
2024
Document type:
Article
/
Project document